Meridian Assay

Independent analytical testing - Cambridge MA

TASK NO.
LUUGPR5
Report MA-KPV-0012 - Rev. 01

CERTIFICATE OF ANALYSIS

KPV - 10 mg


Synthetic tripeptide - sequence KPV - lyophilised

Material	KPV	Client	novumpeptides.com	Received	2026-05-08 at 2-8 C
Batch / lot	KPV-12-PR5	Label claim	10 mg	Analysed	2026-05-09 to 2026-05-10

TEST RESULTS

ATTRIBUTE	RESULT	SPECIFICATION	METHOD	VERDICT
Identity	**Conforms**	Matches reference	MA-MS-014 / LC-HRMS	Conforms
Purity (area %)	**99.33%**	>= 99.00%	MA-UHPLC-031 / UV 214	Pass
Largest single impurity	**0.19%**	<= 0.50%	MA-UHPLC-031 / UV 214	Pass
Total related substances	**0.67%**	<= 1.00%	MA-UHPLC-031 / UV 214	Pass
KPV per vial	**9.99 mg**	9.00-11.00 mg	MA-ASSAY-011 / UHPLC-UV	Pass
Water content	**4.55%**	<= 8.00%	MA-KF-004 / Karl Fischer	Pass
Residual acetonitrile	**210 ppm**	<= 410 ppm	MA-GC-006 / HS-GC-FID	Pass
Residual TFA	**0.10%**	<= 1.00%	MA-IC-003 / ion chromatography	Pass

RP-UHPLC processed trace, UV detection



Record LUUGPR5-PEP-01; duplicate independent preparations. System suitability met retention-time and resolution criteria; blank response was below threshold.

Related species > 0.05%

deletion sequence	0.19%
insertion sequence	0.15%
diastereomeric variant	0.11%
N-terminal variant	0.08%
C-terminal variant	0.06%
unresolved peaks	0.08%

Related species were assigned by orthogonal reference comparison and mass-spectrometric or chromatographic evidence. Mean area percentages; reporting threshold 0.05%.

Conclusion

Identity and quality attributes met the stated criteria. Mean KPV content was 9.99 mg/vial and chromatographic purity was 99.33%.

Identity was established by LC-HRMS against a qualified reference; content and related substances were assessed independently.

Analytical review
Ines Abadi I.Abadi

Quality review
Marcus Oyelaran
Approval date: 2026-05-11 M.Oyelaran

Decision rule: guarded acceptance; reported outcomes account for method uncertainty and remain within the stated project specifications.